Business Wire

CGTN

16.11.2020 10:11:09 CET | Business Wire | Press release

Share
CGTN: What China's 14th Five-Year Plan Means for Yangtze River Economic Belt

Two weeks after China unveiled a blueprint for its economic and social development for the next five years to 2025, Chinese leaders on Saturday laid out relatively specific plans and targets for the Yangtze River Economic Belt.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005494/en/

They included high-quality growth, green growth, opening-up as well as self-innovation.

These agendas were highlighted in a meeting in Nanjing, the capital city of Jiangsu Province, by Chinese President Xi Jinping, who just wrapped up inspection in the province.

Xi, also general secretary of the CPC Central Committee, went to Shanghai on November 12 to mark the 30th anniversary of Pudong's development and opening-up and later inspected Nantong and Yangzhou in Jiangsu.

This was Xi's first domestic inspection tour after the fifth plenary session of the 19th CPC Central Committee from October 26 to 29.

The key CPC meeting reviewed the 14th Five-Year Plan that takes high-quality growth as the goal for 2021-2025 and calls self-sufficiency in technology a strategic pillar for development.

It also said China will develop and urbanize regions, combine efforts to expand domestic demand with supply-side reform as well as widen its market to foreign capital.

Saturday's meeting decoded the grand development strategy for the first time for the vast region covering 11 provinces and municipalities.

At the meeting, Xi was briefed on the super-region's latest developments, and given advice and suggestions for future plans by four senior officials from the central government and chiefs from three provinces.

Xi said the super-region has made a remarkable contribution to China's recovery in the past months, pushing the country ahead of other major economies in pandemic recovery.

The plan to boost the Yangtze River Economic Belt must be consistent with the new development strategy, with an emphasis on a higher-quality growth, Xi said, adding it should be a role model for green growth, regional coordination, opening-up and self-innovation.

Xi said boosting the Yangtze River Economic Belt is of "strategic importance" as it covers 11 provinces and municipalities, from coastal regions Jiangsu and Shanghai to inland Sichuan and Chongqing.

Official data shows the super-region covers roughly one-fifth of China's land and has a population of 600 million, generating more than 40 percent of the country's GDP.

Environment vulnerability is the foremost concern for the sustainable growth of local economies along the river, Xi pointed out, asking officials to prioritize ecological restoration.

Stressing coordination, Xi said governments in the upper, middle and lower reaches of the river should overcome administrative barriers in restoring the ecology and improving mechanism monitoring, warning systems as well as disaster prevention and rescue procedures.

The Yangtze River Basin is now one of the most populated and developed regions in the world, but it also routinely suffers from flood in monsoon season.

This summer, the Yangtze River Basin saw the heaviest rainfall since 1961 and the worst flooding in decades.

According to the Ministry of Water Resources, some 219 people have died or gone missing in the floods and about 634.6 million people have been affected, causing economic losses of 178.96 billion yuan ($25.78 billion).

Speaking of the structural asymmetries of the Yangtze River Economic Belt, Xi said some labor-intensive companies can move their factories from coastal regions to inland areas, so as to stabilize domestic production and supply chain.

As the country's driving force, Xi said the super-region must build modernized industrial and supply chains that are more innovative, secure, reliable and valuable.

To reach the target, the region should invest more in innovation through setting up national and comprehensive innovative labs and giving more support to enterprises, he said.

He also renewed his pledge to open up market access, especially for inland regions, to foreign capital, and he asked officials to better integrate local economies into the Belt and Road Initiative so as to expand foreign investment and trade.

Chongqing and Chengdu, both along the Yangtze River Economic Belt, have already served as junctions of the Belt and Road Initiative.

They launched China-Europe freight train services in 2011 and 2013, respectively. Latest number showed that more than 10,000 freight trains had traveled between the two cities and Europe, accounting for over 40 percent of the total China-Europe train journeys.

Read the original article here .

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye